Cargando…

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma remains a cancer associated with a poor prognosis. For locally advanced pancreatic cancer (LAPC), median overall survival is approximately 16 months. Here we report the case of a 52-year-old LAPC patient treated with chemotherapy followed by chemoradiotherapy that was assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhenc-Gelas, Marion, Cohen, Romain, Cervera, Pascale, Vaillant, Jean-Christophe, André, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652025/ https://www.ncbi.nlm.nih.gov/pubmed/31360557 http://dx.doi.org/10.1155/2019/8598635

Ejemplares similares

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
por: Alhenc-Gelas, Francois, et al.
Publicado: (2020)

Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication
por: Alhenc-Gelas, Francois, et al.
Publicado: (2019)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation
por: Yang, Shifeng, et al.
Publicado: (2018)

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
por: Amintas, Samuel, et al.
Publicado: (2022)

Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma
por: Duconseil, Pauline, et al.
Publicado: (2019)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
por: Grinshpun, Albert, et al.
Publicado: (2019)

Kinins and Kinin Receptors in Cardiovascular and Renal Diseases
por: Girolami, Jean-Pierre, et al.
Publicado: (2021)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Novel Splice Site Mutation in the PROS1 Gene in a Polish Patient with Venous Thromboembolism: c.602-2delA, Splice Acceptor Site of Exon 7
por: Mrożek, Magdalena, et al.
Publicado: (2020)

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
por: Golan, Talia, et al.
Publicado: (2015)

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
por: Hafezi, Shirin, et al.
Publicado: (2021)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
por: Elhariri, Ahmed, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Survival of pancreatic cancer cells lacking KRAS function
por: Muzumdar, Mandar Deepak, et al.
Publicado: (2017)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022)

Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma
por: Dyer, Brandon A, et al.
Publicado: (2015)

Role of radio-ablative technique for optimizing the survival of patients with locally advanced pancreatic adenocarcinoma (Review)
por: Iancu, Ioana, et al.
Publicado: (2021)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
por: Barcellini, Amelia, et al.
Publicado: (2020)

Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice
por: Cáceres, Marta, et al.
Publicado: (2020)

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)
por: Vernerey, Dewi, et al.
Publicado: (2016)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
por: Aran, Veronica, et al.
Publicado: (2021)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2021)

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
por: Ardalan, Bach, et al.
Publicado: (2021)

Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice
por: Desposito, Dorinne, et al.
Publicado: (2017)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_roogcbg7rpk0mfuuge5se9dkmd